Stocktoria
Dare Bioscience, Inc. DARE
Dare Bioscience, Inc. (DARE) earns a Piotroski F-score of 3/9 (weak financial health). It does not currently pay a dividend. FY2025 revenue was $1.0M at a -1300.7% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| DARE | Dare Bioscience, Inc. | 3/9 | — | — | — |
| SXTP | 60 DEGREES PHARMACEUTICALS, INC. | 3/9 | — | — | — |
| STTK | Shattuck Labs, Inc. | 3/9 | -3.77 | — | — |
| RNXT | RenovoRx, Inc. | 2/9 | — | — | — |
| SXTC | China SXT Pharmaceuticals, Inc. | 3/9 | 2.19 | — | — |
| RFL | Rafael Holdings, Inc. | 3/9 | 0.8 | — | — |
| LGVN | Longeveron Inc. | 2/9 | — | — | — |
About Dare Bioscience, Inc.
Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. The company offers XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis. It also develops Ovaprene, a hormone-free monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia for the treatment of female sexual arousal disorder; DARE-HRT1 to treat vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of dyspareunia or pain during sexual intercourse; and DARE-HPV, a fixed-dose formulation of lopinavir and ritonavir in a soft gel vaginal insert to treat genital human papillomavirus (HPV) infection, cervical intraepithelial neoplasia, and other HPV-related pathologies. In addition, the company develops DARE-PDM1, a hydrogel formulation of diclofenac for vaginal administration to treat primary dysmenorrhea; DARE-204 and DARE-214, injectable formulations of etonogestrel that provides contraception over 6-month and 12-month periods; DARE-FRT1 and DARE-PTB1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB2 for the prevention of preterm birth. Further, it develops DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design controlled contraceptive option; DARE-RH1, an approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein; and DARE-GML, which delivers antimicrobial glycerol monolaurate intravaginally. Daré Bioscience, Inc. was founded in 2015 and is headquartered in San Diego, California.
FAQ
Is DARE financially healthy?
Dare Bioscience, Inc.'s Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak).
Does DARE pay a dividend?
No, Dare Bioscience, Inc. does not currently pay a dividend.
How profitable is DARE?
In FY2025, Dare Bioscience, Inc. had a net margin of -1300.7% and a return on equity of -471.4%.
What is the analyst price target for DARE?
The average Wall-Street price target for Dare Bioscience, Inc. is $9.67, about 571.3% above the recent price, from 3 analysts.
Is DARE a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Dare Bioscience, Inc.: a Piotroski F-score of 3/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.